5'-Methyl-2'-deoxycytidine-5'-phosphorothioate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5'-Methyl-2'-deoxycytidine-5'-phosphorothioate
• 英文别名: 4-amino-1-[(2R,4S,5R)-5-(dihydroxyphosphinothioyloxymethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidin-2-one
• 化学式: C₁₀H₁₆N₃O₆PS
• 分子量: 337.29
• InChiKey: UZWQYGFEEXJOHY-XLPZGREQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  170
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Methods of treating colorectal cancer
  申请人：Nogra Pharma Limited

  公开号：US10006029B2

  公开（公告）日：2018-06-26

  Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer.

  本文公开了使用SMAD7表达或功能的特异性抑制剂治疗/和或预防结直肠癌的方法。还公开了含有SMAD7抑制剂的治疗和/或预防结直肠癌的药物组合物，以及含有SMAD7抑制剂的用于治疗和/或预防结直肠癌的药物的制造。
• Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
  申请人：Nogra Pharma Limited

  公开号：US10081809B2

  公开（公告）日：2018-09-25

  Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.

  本文公开了使用 SMAD7 表达或功能的特异性抑制剂治疗/和或预防糖尿病的方法。还公开了使用 SMAD7 表达或功能特异性抑制剂促进器官和/或细胞（如胰岛细胞）移植后存活的方法。
• Methods for treating inflammatory bowel disease
  申请人：Nogra Pharma Limited

  公开号：US10473669B2

  公开（公告）日：2019-11-12

  Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.

  公开了用抗SMAD7疗法（如SMAD7反义寡核苷酸）治疗IBD患者以降低CRP水平的方法。还公开了基于CRP水平使用抗SMAD7疗法（如SMAD7反义寡核苷酸）治疗和管理受试者IBD的方法。还公开了确定IBD患者是否对抗SMAD7疗法有反应或可能有反应的方法。CRP水平的降低可能与IBD缓解或CDAI评分的降低相关。本发明还涉及使用抗SMAD7疗法（如反义寡核苷酸）与附加药剂联合治疗IBD。本发明还涉及相关药物组合物和试剂盒。
• METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION
  申请人：Nogra Pharma Limited

  公开号：EP2839004B1

  公开（公告）日：2019-06-12
• METHODS OF TREATING COLORECTAL CANCER
  申请人：Nogra Pharma Limited

  公开号：EP2970419A1

  公开（公告）日：2016-01-20